Wani bincike na baya-bayan nan da aka buga a mujallar Cellular and Molecular Gastroenterology and Hepatology ya nuna cewa maye gurbi da ake kira ATRX na iya haifar da karuwar kamuwa da cutar sankara ta pancreatic da pancreatic cancer a cikin mata. Wannan binciken shine farkon gano abubuwan haɗari na ƙayyadaddun jinsin jima'i don ciwon daji na pancreatic.
The team used a preclinical model to examine the effect of ATRX mutations on the adult pancreas. They deleted the ATRX gene and then studied its effect on ciwon cizon sauro susceptibility. The team found that the deletion of the ATRX gene in women increased the susceptibility to pancreatitis-related pancreatic damage and accelerated the progression of pancreatic cancer. A cikin maza, maye gurbi na ATRX baya ƙara haɗarin lalacewar pancreatic, kuma a zahiri yana rage ci gaban ciwon daji na pancreatic.
The team ‘s preclinical results were compared with human samples from the International Cancer Genome Alliance database, which includes whole-genome sequence analysis of 729 patients. Ƙungiyar binciken ta gano cewa 19% na marasa lafiya suna dauke da maye gurbi a cikin tsawon kwayar ATRX, ciki har da yankunan da ba su da lambar, wanda 70% mata ne. Kodayake yawancin maye gurbi ba sa kawo cikas ga tsarin furotin na ATRX, maye gurbi da aka annabta zai shafi aikin ATRX yana faruwa kusan a cikin mata.
Masanin kimiyyar Lawson kuma mataimakin farfesa Dokta Chris Pin ya ce, “Canwon daji cuta ce mai matukar muni da ake gano ta a matakin ci gaba. Marasa lafiya yawanci ba sa amsa hanyoyin kwantar da hankali na yau da kullun, kuma matsakaicin tsawon rayuwar marasa lafiya shine bayan ganewar asali Kasa da watanni 6. "Pancreatitis cuta ce da ke tattare da kumburin ƙwayar cuta kuma ɗayan mahimman abubuwan haɗari don haɓaka ciwon daji na pancreatic. Ko da yake ana buƙatar ƙarin bincike, matan da ke fama da pancreatitis za a iya gano wata rana a matsayin rukuni mai haɗari, kuma wannan maye gurbin kwayoyin halitta ya kamata a duba.
In a follow-up study, Dr. Pin will work with French researchers to study patient tumo samples in a new preclinical model. Their goal is to better understand the mechanism of ATRX mutations as a gender-specific risk factor. In order to develop better diagnosis and treatment methods for women carrying this mutation.
